|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2000-10-10
|
|
pubmed:abstractText |
Donor lymphocyte infusion (DLI) is currently standard therapy for relapse of malignancies after allogeneic BMT. Several observations suggest that both normal and leukemic progenitor cells of host origin constitute effective target cells for donor-derived lymphocytes. To prevent relapse of sickle cell disease (SCD), a child with evidence of decreasing mixed chimerism received DLIs 8 months after allogeneic BMT for SCD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0041-1132
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1071-3
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10988309-Bone Marrow Transplantation,
pubmed-meshheading:10988309-Child, Preschool,
pubmed-meshheading:10988309-Hematopoiesis,
pubmed-meshheading:10988309-Humans,
pubmed-meshheading:10988309-In Situ Hybridization, Fluorescence,
pubmed-meshheading:10988309-Infant,
pubmed-meshheading:10988309-Lymphocyte Transfusion,
pubmed-meshheading:10988309-Male,
pubmed-meshheading:10988309-Sickle Cell Trait,
pubmed-meshheading:10988309-Tissue Donors,
pubmed-meshheading:10988309-Transplantation, Homologous
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease.
|
|
pubmed:affiliation |
Division of Hematology, Department of Medicine, University of Liège, Liège, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
